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Colorectal cancer is the fourth leading malignancy, and the second
leading cause of cancer death (National Cancer Institute of
Canada, 1997). Metastases are present in 15% of patients at the
time of diagnosis, and will develop in another 25% at some point
in time. Except in a small minority of surgically resected cases
(Foster and Berman, 1977), metastatic disease is uniformly fatal,
with a median survival of 11 months in patients selected for
clinical trials (Advanced Colorectal Cancer Meta-analysis Project,
1992). Chemotherapy, particularly fluoropyrimidines are used
extensively for the treatment of colorectal cancer, though some
physicians are skeptical regarding its benefits given the poor
response rates reported, with pooled estimates of 11–23%
(Advanced Colorectal Cancer Meta-analysis Project, 1992; Meta-
analysis Group in Cancer, 1998).
Trials involving an observation or supportive care arm in
advanced malignancies are difficult to perform, suffering from
poor accrual, dropout and crossover. Therefore, any such available
data are valuable, as they are not easily obtained.
Existing trials comparing chemotherapy with supportive care
are not widely known, given their small size. A leading oncology
text only references one study on this topic (Hine and Dykes,
1984; Cohen et al, 1997). This results in uncertainty for both
patient and physician contemplating systemic therapy.
To estimate the magnitude of survival benefit of chemotherapy,
a meta-analysis of randomized trials comparing chemotherapy
with either observation or supportive care alone for metastatic
colorectal cancer was conducted.
METHODS
Literature search
To identify randomized controlled trials of chemotherapy in
metastatic colorectal cancer patients, a systematic search of the
MEDLINE database from 1976 to 1998, the CANCERLIT
database from 1983 to 1998, and the CURRENT CONTENTS
database from 1997 was conducted using the following medical
subject heading terms: colonic neoplasms, human, random alloca-
tion, research design, palliative care, and quality of life. In addi-
tion, the following text words were used in combination: random,
colon, rectum, rectal, colorectal, cancer, carcinoma, adenocarci-
noma, advanced, metastatic, metastases, metastasis, supportive,
observation, delayed and control. The reference lists of retrieved
articles were reviewed and further relevant studies were obtained.
A hand search of recently published journals was performed, as
well as a review of abstracts from proceedings of recent inter-
national meetings.
Inclusion criteria
In order to be included in the pooled analysis, trials must have
involved patients with stage IV or unresectable advanced
colorectal cancer. Patients must have been randomized to either
initial chemotherapy or initial management without chemotherapy,
described as either initial observation or supportive care alone.
Assessment for publication bias
A funnel plot was generated to assess for possible publication bias
(Lau et al, 1997). Trial size was plotted against the risk ratio for
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left unpublished.
Quality assessment
All randomized controlled trials comparing an active treatment
arm using antineoplastics with a control arm using initial observa-
tion or supportive care were retrieved. Trials were assessed inde-
pendently for quality of trial reporting by three reviewers using
components of the Jadad instrument (Jadad et al, 1996), and for
analysis performed on an intent-to-treat basis. Studies were
excluded if both survival curves and survival data were not
available. When disagreement existed, it was resolved through
conference.
Data extraction
Using published survival curves or directly published data, the
1-year and 2-year mortality was determined for the chemotherapy
and supportive care arms. Data regarding response rates, quality of
life and toxicity were summarized quantitatively and qualitatively.
Median, 1-year and 2-year survivals in each trial were also
summarized.
Primary end point
In the primary analysis, the 1-year overall survival of patients
treated with chemotherapy versus supportive care was assessed.
For each study, a relative risk estimate was calculated as the
mortality in the chemotherapy arm divided by the mortality in the
control arm. The individual relative risk estimates were pooled and
a 95% confidence interval (CI) was provided using a random-
effects model (DerSimonian and Laird, 1986) computed with
Meta-Analyst 0.998 (c 1998, J Lau). Survival was considered
statistically significant if the 95% CI for the relative risk did not
encompass 1. Heterogeneity between the trials was determined by
calculating the Q statistic using a c2 test (Fleiss, 1981).
Secondary end points
Secondary outcome measures included 2-year overall survival,
quality of life and a sensitivity analysis of 1-year overall survival.
The sensitivity analysis was conducted by combining subgroups of
trials based on patient and treatment differences between trials.
Subgroups compared include carcinoembryonic antigen (CEA)-
positive only versus measurable or evaluable disease, localized
hepatic metastases versus diffuse metastatic spread, and route of
administration.
RESULTS
Trials selected
From the initial search, 860 abstracts were identified and reviewed
online. From these, 12 articles were retrieved of which six met the
inclusion criteria. A further three trials were identified by refer-
ence and hand search of journals.
Seven of these nine randomized controlled trials were used in
the meta-analysis. They had a total of 614 patients comparing
chemotherapy to an initial observation arm in patients with
metastatic colorectal cancer (Hine and Dykes, 1984; Nordic
Gastrointestinal Tumour Adjuvant Therapy Group (NGTATG),
1992; Rougier et al, 1992; Scheithauer et al, 1993; Allen-Mersh
et al, 1994; Hafstrom et al, 1994; Glimelius et al, 1995). These are
listed in Table 1, along with a brief description of treatment sched-
ules. One trial by Beretta et al (1994) published only in abstract
form was excluded due to insufficient data reported for survival
analysis. Cunningham et al (1998) was excluded as it involved
second-line therapy. Chemotherapy was fluoropyrimidine based
all of the trials (5-fluorouracil (5-Fu) in five and FUDR in two),
and was administered by a variety of routes (intravenous in four,
hepatic intra-arterial in two, and portal venous in one). Statistically
there was no significant heterogeneity in 1-year survival between
trials (Q statistic = 3.53, P > 0.1). A funnel plot (not shown) did
not identify any evidence of publication bias, though this cannot
be entirely excluded.
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Table 1 Randomized clinical trials comparing chemotherapy versus initial observation in metastatic colorectal cancer
Trial No. of Treatment Randomization Intention Median survival 1-year 2-year
patients method to treat in months (P-value) survival survival
described
Hine et al 26 5-FU/meCCNU i.v. No Yes 16 (= 1.0) 73% 23%
26 Observation ± 5-FU 16 73% 23%
Rougier et al 81 HAI FUDR No Yes 15 (NR) 63% 23%
82 Observation or 5-FU 11 44% 13%
NGTATG 92 MTX/LV/5-FU i.v. Yes Yes 15 (= 0.13) 55% 15%
90 Observation/delayed CT 9 38% 12%
Scheithauer et al 24 CDDP/LV/5-FU i.v. Yes Noa 11 (= 0.006) 42% 12%
12 BSC 5 8% 0%
Hafstrom et al 32 HA occlusion/intraportal 5-FU No Nob 16 (NR) 62% 31%
28 Observation ± 5-FU/LV 8 36% 18%
Allen-Mersh et al 51 HAI FUDR No Yes 13 (= 0.3) 51% 18%
49 BSC 7 35% 16%
Glimelius et al 11 5-FU/LV i.v. No Yes 12 (= 0.1) 45% NR
10 Observation ± 5-FU/LV 6 30% NR
aExcluded 2 control patients and 2 treatment patients not accepting assignment after randomization; no details given. bExcluded 2 control patients and 2
treatment patients not meeting inclusion criteria after randomization. i.v., intravenous; HAI, hepatic-arterial infusion; 5-FU, 5-fluorouracil; FUDR, fluorouridine-
deoxyribose; MTX, methotrexate; LV, leucovorin; BSC, best supportive care; NR, not reported.Quality assessment
None of the available trials used placebo controls and there was no
attempt to blind either patient or physician. In choosing the hard
end point of mortality, the risk of bias by the assessing physician is
reduced. Trial quality is reported in Table 1. Two trials violated
intent-to-treat analysis with inappropriate exclusion of a total of
four control patients and four treatment patients.
Patient characteristics
All trials, except Hine and Dyke (1984), involved patients with
measurable or evaluable disease. This trial included patients with
rising CEA without other evidence of metastases. Patient charac-
teristics (where published) are recorded in Table 2. The median
age was 60 years. Fifty-seven per cent were male. Sixty-eight per
cent were colon primaries and 32% rectal. Patients were well
balanced between groups for sex, age and performance status.
Most patients had excellent performance status (Karnofsky perfor-
mance status 80–100) at entry into the trials.
Chemotherapy in the supportive care arm
Many trials allowed in their design for delayed or discretionary use
of chemotherapy for patients randomized to the observation or
supportive care arm. Chemotherapy was received by 12–57% of
control patients, as reported in Figure 1. These patients were all
analysed on an intention-to-treat basis. Subsequent chemotherapy
use by patients in the control arm did not to reduce the benefit of
use of initial chemotherapy (P = 0.682).
Pooled analysis
Figure 2 shows the relative risk of 1-year mortality in each trial
with individual and pooled estimates. Chemotherapy resulted in a
significantly lower risk of mortality at 1 year compared to no
chemotherapy (risk ratio 0.69; 95% CI 0.60–0.81, P < 0.00001).
The odds ratio for 1-year mortality was 0.48 (95% CI 0.34–0.66,
P = 0.00001). In patients with a 42% 1-year mortality risk, which
was the rate for the pooled sample from these seven trials of gener-
ally good performance status patients, the number needed-to-treat
(NNT) with chemotherapy to result in one additional patient alive
at 1 year is 5.4 patients (95% CI 3.9–9.2) with a risk difference
of 1-year mortality of –0.1835 (95% CI –0.2586 to –0.1084,
P < 0.00001).
Figure 3 shows the relative risk of two-year mortality in each
trial with individual and pooled estimates. There was no significant
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Table 2 Patient characteristics
Trial Accrual Treatment arm No. of M/F Median Colon/ Performance
period patients age rectum status
Hine et al ??–1983 5-FU/meCCNU 26 18/8 61 NR KPS 100%
Observation ± 5-FU 26 15/11 59 NR KPS 100%
Rougier et al 1985–1988 HAI FUDR 81 47/34 59 52/29 94% ECOG 0–1
Observation or 5-FU 82 44/38 61 58/24 92% ECOG 0–1
NGTATG 1985–1990 MTX/LV/5-FU 92 63/37 60 62/38 84% KPS 100%
Observation/delayed CT 90 51/49 60 79/21 84% KPS 100%
Scheithauer et al 1988–1989 CDDP/LV/5-FU 24 10/14 63 14/10 67% ECOG 0–1
BSC 12 7/5 69 8/4 67% ECOG 0–1
Hafstrom et al 1984–1992 HA occlusion/intraportal 5-FU 32 16/12 57 17/11 NR
Observation ± 5-FU/LV 28 10/16 62 20/6 NR
Allen-Mersh et al 1988–1993 HAI FUDR 51 34/17 55 NR KPS 90%
BSC 49 29/20 59 NR KPS 90%
Glimelius et al 1991–1992 5-FU/LV 11 NR 65 6/5 KPS 78%
Observation ± 5-FU/LV 10 NR 61 6/4 KPS 80%
NR, not reported; M/F, male/female; KPS, Karnofsky performance status; HAI, hepatic-arterial infusion; 5-FU, 5-fluorouracil; FUDR, fluorouridine-deoxyribose;
MTX, methotrexate; LV, leucovorin; BSC, best supportive care.
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Figure 1 A plot illustrating the effect of chemotherapy use in control arm
patients (contamination) on risk ratio of 1-year mortality
Figure 2 A plot of risk ratio of 1-year mortality with 95% confidence
intervals (CI) for each trial and the pooled estimate
Risk Ratio 1Year Mortality
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Pooled
Glimeliusdifference, with a relative risk of 0.93 (95% CI 0.87–1.00,
P = 0.053). The risk difference was –0.0617 (95% CI –0.11 to
–0.0035, P = 0.038) and the odds ratio was 0.66 (95% CI
0.43–1.03,  P = 0.067).
Sensitivity analysis for 1-year mortality results
Figure 4 shows estimates for risk ratio of 1-year mortality for
patients treated with chemotherapy for various patient and treat-
ment subgroups through between trial comparisons. All subgroups
appeared to benefit from chemotherapy, except CEA-only positive
patients, for whom there was insufficient power to exclude a
benefit. Sensitivity analysis for 2-year overall survival found that
only the subgroup with measurable or evaluable disease had a
statistically significant improvement in survival, with a risk ratio
for 2-year mortality of 0.93 (95% CI 0.86–1.00, P = 0.047).
Quality of life
Quality of life was evaluated in four trials by a variety of measures,
including the FLIC (Scheithauer et al, 1993), the Rotterdam check-
list and the Hospital Anxiety and Depression Scale (Allen-Mersh et
al, 1994). In these studies, there was either maintenance of, or
improvement in, the scores of the chemotherapy arm compared to
the initial observation arm (Table 3).
Toxicity
Toxicity was not quantitatively documented by many of the trials.
Where documented, toxicity was generally mild to moderate. In
Hafstrom et al (1984), there was unacceptable toxicity in the
chemotherapy arm with two patient deaths related to incorrect
dosages of chemotherapy used for a portal venous infusion, consti-
tuting major protocol violations. In Rougier et al (1992), hepatic
arterial infusion was associated with a 25% incidence of sclerosing
cholangitis by 1 year.
DISCUSSION
Before interpreting the data, some caution is advised with meta-
analysis of published data. Publication bias (the existence of
missed unpublished negative studies) may result in an over-
estimation of the true treatment effect, which would not occur with
a single, large randomized study. The funnel plot did not suggest a
publication bias, but this cannot be excluded. One trial published
in abstract form, which included 88 elderly patients with colorectal
cancer, was not included, as data was not available. This would
represent 12% of the total sample had they been included. The
abstract suggested a survival benefit, but there was inadequate
information to include in the pooled analysis.
Caution must also be taken in interpretation of the subgroup
analyses based on between-trial comparisons. They do not
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Figure 3 A plot of risk ratio of 2-year mortality with 95% confidence
intervals (CI) for each trial and the pooled estimate
Figure 4 A plot of risk ratio of 1-year mortality with the 95% confidence
intervals (CI) for various subgroups of trials based on characteristics of
patients at entry (measurable/evaluable versus CEA-positive only), route of
administration of chemotherapy, and the quality of trial reporting
Table 3 Quality of life measures
Trial Measure Initial Control P-value
chemotherapy
NGTATG Median symptom-free survival 10 months 2 months < 0.001
Median progression-free survival 8 months 3 months < 0.001
Scheithauer et al Preservation of QOL by FLIC score 67% 62% > 0.5
Allen-Mersh et al Rotterdam checklist and HAD scale – – > 0.5
Glimelius et al Median quality-adjusted survival 9.6 months 4.2 months NR
QOL, Quality of life; FLIC, Functional Living Index for Cancer; HAD, Hospital Anxiety and Depression; NR, Not reported.adequately take into account differences between patients within
trials. These analyses may be hypothesis generating, but many
comparisons will be better assessed by individual patient data
meta-analysis (for example the effect of performance status on
treatment effect), or ideally randomized controlled trials (for
example, whether HAI is superior to intravenous chemotherapy).
This meta-analysis of randomized controlled trials shows that
chemotherapy results in a significant survival advantage compared
with non-chemotherapy management. Of patients randomized to
chemotherapy, there was an 18% absolute reduction in 1-year
mortality, resulting in one additional patient alive for every 5.4
patients treated. This NNT would apply to a patient with a baseline
1-year mortality of 42%, which was the pooled 1-year mortality
rate in these combined trials of generally good performance status
patients. The benefit in terms of a median survival difference
varies between populations treated, and ranged from 0 to 8 months
difference (median 6 months). To determine the difference more
precisely, an individual patient data meta-analysis would be
required.
The benefit appears consistent for a variety of regimens and
regardless of route of administration. The drugs used varied
between trials, and many were inferior by today’s standards.
Although all included fluoropyrimidines, the basis of all conven-
tional standard first-line chemotherapy regimens, these were
combined with drugs such as cisplatin, methotrexate and methyl
CCNU, drugs which are considered to be inferior, unnecessary,
or associated with increased toxicity compared to 5-FU and
leucovorin (LV) combinations.
Similarly, the route of administration did not appear to alter the
survival benefit. For patients with localized unresectable liver
metastases, both local therapies, such as portal venous infusion
and hepatic arterial infusion, and systemic treatment appear to
confer a survival benefit.
The patients in Hine and Dyke (1984) were CEA-positive
without other evidence of measurable or evaluable disease, repre-
senting an earlier stage of disease than the other trials. The sample
size was too small to detect a potentially clinically significant
difference. No other trials have evaluated chemotherapy in this
setting, making recommendations difficult. This trial does not
support or counter the use of chemotherapy in this population,
though many would feel uncomfortable withholding treatment in
this subgroup. A randomized trial using conventional
chemotherapy would be valuable in this population, though
accrual would be difficult.
The results of this meta-analysis are further supported by
Cunningham et al (1998) comparing second-line irinotecan to
supportive care in this same population. This demonstrated a
36.2% 1-year survival in this irinotecan group versus 13.8% in the
supportive-care group. This is a risk ratio of 0.74 for 1-year
mortality. The survival benefit remained significant after adjust-
ment for prognostic factors in a multivariate analysis (P = 0.001).
The trials evaluated suffer some methodological problems
related to having a non-treatment arm. In particular, there was no
blinding, risking bias in softer end points such as quality of life 
or response rates. The use of hard end points, such as mortality,
will reduce this risk. The inappropriate exclusion of eight patients
from analyses in these trials may have resulted in an over- or
underestimation of the true treatment effect.
Patients included in these trials were of generally high perfor-
mance status. One cannot necessarily generalize these results to
patients in poorer general condition. It is interesting to note,
however, that the difference in median survival was as significant
in the trial by Scheithauer et al (1993), which included patients
with poorer performance status, suggesting the survival benefit
may not be limited to those with high performance status.
One question that remains unanswered is whether initial or
delayed chemotherapy is superior in an asymptomatic patient. In
some of these trials there was a high rate of delayed use of
chemotherapy by patients in the control arm. The NGTATG (1992)
trial in particular had chemotherapy use in 57% of the control
patients, allowed as part of the study design. This trial suggests
that immediate chemotherapy is superior to delayed
chemotherapy. The answer is being addressed in ongoing trials,
including an Australian study and an NCI Canada study (NCIC
CO-10) which has closed prematurely due to poor accrual. The
pooled results from these two studies may clarify this issue.
The fact that many patients in the control arms received
chemotherapy as part of their supportive care would have weak-
ened any observed difference between the treatment and observa-
tion arms. This crossover to anti-tumour therapy may have
weakened any survival benefit observed, thus strengthening the
results of this meta-analysis.
Despite the demonstrated benefit, the outcomes of patients
treated with chemotherapy are still poor. Much work is needed,
particularly in the arena of new drug development, in order to
improve the outcome for patients with colorectal cancer.
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